drugset / Trial / NCT04839341
Study to Evaluate PK and Safety With Uproleselan Combined With Chemotherapy to Treat Chinese R/R AML Patients
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety and tolerability of uproleselan(GMI-1271), a specific E-selectin antagonist, and characterize the pharmacokinetic (PK) profile of uproleselan, in combination with chemotherapy to treat Chinese relapsed/refractory AML patients.
Timeline
- Start
- 2021-02-24
- Primary completion
- 2024-06-28
- Completion
- 2024-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Uproleselan | Small molecule | — | — |